JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has ...

JERUSALEM and WILMINGTON, Del., March 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and Healthcare Capital ...

The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data ...

JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, today announced that the FDA has ...

The first use of Alpha DaRT in a human brain tumor sets a new clinical precedent and may signal a company on the verge of broader recognition. Alpha Tau Medical (NASDAQ: DRTS), a company still flying ...

- Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive ...

- Interim Jan-2025 results from three trials of Alpha DaRT® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate, impressive ...

Alpha DaRT, a unique localized alpha radiation therapy, has shown potential best-in-class efficacy and safety across multiple solid tumors. Currently enrolling patients in cSCC, HNSCC, pancreatic, and ...

Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) rose 62.4% to $3.15 in pre-market trading after falling 11% on Monday. Tivic Health Systems inked a pact to make its products available on ...

Alpha Tau Medical’s proprietary Alpha DaRT device safely delivers alpha radiation with localized precision to treat cancers. Alpha Tau is waiting for FDA feedback to initiate a US pivotal trial in ...

Alpha Tau Medical didn't have any news today to cause its stock to soar. Investors' excitement appears to be increasing about the potential for the company's cancer radiation therapy. The company didn ...